🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,867 results for “De” Clear

  1. SERTRALINE , LITHIUM , ESCITALOPRAM , QUETIAPINE, VENLAFAXINE , VALPROIC ACID , BUPROPION

    Disc Medicine

    Bipolar depression

    phase 3 small molecule active

    1 trial

  2. SEVOFLURANE, DEXMEDETOMIDINE HYDROCHLORIDE

    The George Institute

    Children under the age of 2 years having surgery lasting at least 2 hours

    phase 3 small molecule active

    1 trial

  3. SHP465

    Takeda

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    4 trials

  4. SHP465 12.5mg capsules (one capsule daily)

    Takeda

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    1 trial

  5. SHP640

    Takeda

    Adenoviral Conjunctivitis

    phase 3 small molecule terminated

    2 trials

  6. SOC plus 15mg/kg EB05 IV

    Edesa Biotech

    COVID-19

    phase 3 mab on hold

    1 trial

  7. SODIO CLORURO 0,9% BAXTER Soluzione per infusione, KETAMINA MOLTENI 50 mg/ml soluzione iniettabile

    Talion

    Major Depressive Disorder (MDD)

    phase 3 small molecule active

    1 trial

  8. SODIO CLORURO 0,9% BAXTER Soluzione per infusione, KETAMINA MOLTENI 50 mg/ml soluzione iniettabile

    Talion

    Major Depressive Disorder (MDD)

    phase 3 small molecule active

    1 trial

  9. SODIUM CHLORIDE , CAEL-101

    Alexion Europe SAS

    Stage IIIb cardiac AL amyloidosis

    phase 3 small molecule active

    1 trial

  10. SODIUM CHLORIDE , CAEL-101

    Alexion Europe SAS

    stage IIIa cardiac AL amyloidosis

    phase 3 small molecule active

    1 trial

  11. SODIUM CHLORIDE , DYNE-101

    Dyne Therapeutics

    Myotonic Dystrophy Type 1

    phase 3 small molecule active

    1 trial

  12. SODIUM CHLORIDE , RITUXIMAB, MYCOPHENOLIC ACID

    Tour Hekla

    Intersitial lung disease related to systemic sclerosis

    phase 3 small molecule active

    1 trial

  13. SODIUM CHLORIDE, Gardasil 9 suspension for injection in a pre-filled syringe. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed)

    Pari Pharma GmbH

    HPV vaccine

    phase 3 small molecule active

    1 trial

  14. SODIUM CHLORIDE, HYDROCORTISONE UPJOHN 100 mg, préparation injectable, Placebo of hydrocortisone 100 mg, Reverpleg 40 U.I./2 ml solution à diluer pour perfusion

    Pari Pharma GmbH

    Adult cardiac arrest patients with sustained ROSC and hemodynamic failure due to post-resuscitation syndrome

    phase 3 small molecule active

    1 trial

  15. SODIUM CHLORIDE, Kineret 100 mg/0.67 ml solution for injection in pre-filled syringe.

    Pari Pharma GmbH

    PEDIATRIC ACUTE MYOCARDITIS

    phase 3 small molecule active

    1 trial

  16. SODIUM CHLORIDE, LEVETIRACETAM VIATRIS 100 mg/ml, solution à diluer pour perfusion

    Pari Pharma GmbH

    Adult ICU patients with septic shock

    phase 3 small molecule active

    1 trial

  17. SODIUM CHLORIDE, MYCOPHENOLATE MOFETIL, GLUCOSE, Oleclumab, MYCOPHENOLATE MOFETIL, IMFINZI 50 mg/mL concentrate for solution for infusion., Monalizumab, IMFINZI 50 mg/mL concentrate for solution for infusion., INFLIXIMAB

    AstraZeneca AB

    Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  18. SODIUM CHLORIDE, ROPIVACAINE

    Pari Pharma GmbH

    Cancer surgery

    phase 3 small molecule active

    1 trial

  19. SODIUM CHLORIDE, Truxima 500 mg concentrate for solution for infusion

    Pari Pharma GmbH

    Patient with stabilized SSc-ILD (as defined by a decline of FVC ≤ 5%) following RTX induction treatment

    phase 3 small molecule active

    1 trial

  20. SODIUM CHLORIDE, VRDN-001 (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor)

    Viridian Pharma Ltd

    Thyroid eye disease

    phase 3 small molecule active

    1 trial

  21. SODIUM CHLORIDE, VRDN-001 (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor), VRDN-001 (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor)

    Viridian Pharma Ltd

    Thyroid eye disease (TED)

    phase 3 small molecule active

    1 trial

  22. SOTORASIB, Dexamethasone 2mg Tablets, DOCETAXEL

    Amgen

    Previously treated locally advanced and unresectable or metastatic non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation

    phase 3 small molecule active

    1 trial

  23. SOTYKTU 6 mg film-coated tablets, Matching Placebo for Deucravacitinib, SOTYKTU 6 mg film-coated tablets, SOTYKTU 6 mg film-coated tablets, ZASOCITINIB, SOTYKTU 6 mg film-coated tablets, Matching Placebo for TAK-279

    Takeda

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  24. SPD422 (anagrelide hydrochloride)

    Takeda

    Essential Thrombocythemia (ET)

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources